Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:ARQT NASDAQ:PGEN NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$37.24-1.4%$40.25$26.20▼$63.50$1.71B1.44760,438 shs526,833 shsARQTArcutis Biotherapeutics$14.52+1.6%$14.18$7.86▼$17.75$1.73B1.842.14 million shs1.26 million shsPGENPrecigen$1.76+5.4%$1.57$0.65▼$2.17$519.52M1.871.98 million shs2.29 million shsSPRYARS Pharmaceuticals$17.38+1.2%$16.43$8.91▼$18.90$1.71B0.91.51 million shs1.20 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%-7.52%-20.61%-4.16%-14.34%ARQTArcutis Biotherapeutics0.00%-3.84%+4.19%-7.27%+54.49%PGENPrecigen0.00%+6.37%+2.77%+9.87%+21.01%SPRYARS Pharmaceuticals0.00%-3.86%+4.22%+20.48%+73.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics2.5429 of 5 stars3.50.00.00.03.64.20.0ARQTArcutis Biotherapeutics2.8702 of 5 stars3.43.00.00.03.41.70.6PGENPrecigen3.9966 of 5 stars3.51.00.04.73.11.70.6SPRYARS Pharmaceuticals3.0226 of 5 stars3.62.00.00.01.94.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 3.00Buy$99.00165.02% UpsideARQTArcutis Biotherapeutics 2.83Moderate Buy$19.4032.83% UpsidePGENPrecigen 3.00Buy$6.00236.13% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.0078.37% UpsideCurrent Analyst Ratings BreakdownLatest PGEN, APGE, SPRY, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/25/2025ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.007/7/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/7/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.007/7/2025APGEApogee TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $115.007/2/2025APGEApogee TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$116.006/12/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.005/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/15/2025PGENPrecigenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 8/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/AARQTArcutis Biotherapeutics$212.82M8.18N/AN/A$1.35 per share10.82PGENPrecigen$3.92M134.41N/AN/A$0.13 per share13.73SPRYARS Pharmaceuticals$89.15M19.15N/AN/A$2.64 per share6.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)ARQTArcutis Biotherapeutics-$140.04M-$1.04N/AN/AN/A-60.95%-80.66%-32.94%8/6/2025 (Estimated)PGENPrecigen-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)Latest PGEN, APGE, SPRY, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PGENPrecigen-$0.14N/AN/AN/A$0.67 millionN/A8/11/2025Q2 2025APGEApogee Therapeutics-$1.08N/AN/AN/AN/AN/A8/6/2025Q2 2025ARQTArcutis Biotherapeutics-$0.19N/AN/AN/A$72.70 millionN/A8/5/2025Q2 2025SPRYARS Pharmaceuticals-$0.42N/AN/AN/A$12.92 millionN/A5/14/2025Q1 2025PGENPrecigen-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A15.8215.82ARQTArcutis Biotherapeutics0.753.553.37PGENPrecigenN/A3.533.53SPRYARS Pharmaceuticals0.3011.0010.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%ARQTArcutis BiotherapeuticsN/APGENPrecigen33.51%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%ARQTArcutis Biotherapeutics9.40%PGENPrecigen47.10%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.05 million26.35 millionOptionableARQTArcutis Biotherapeutics150119.20 million108.00 millionOptionablePGENPrecigen190295.18 million156.15 millionOptionableSPRYARS Pharmaceuticals9098.21 million65.31 millionOptionablePGEN, APGE, SPRY, and ARQT HeadlinesRecent News About These CompaniesHere's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price StrengthAugust 4 at 12:37 PM | msn.comARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial ResultsAugust 4 at 8:00 AM | globenewswire.com14,780 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Foster & Motley Inc.August 3 at 5:28 AM | marketbeat.comARS Pharmaceuticals (SPRY) Expected to Announce Quarterly Earnings on TuesdayJuly 30, 2025 | marketbeat.comAnalysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out forJuly 29, 2025 | zacks.comSchulhoff & Co. Inc. Purchases Shares of 40,500 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 28, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Rating Lowered to Sell at Wall Street ZenJuly 28, 2025 | americanbankingnews.comKnights of Columbus Asset Advisors LLC Invests $543,000 in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 27, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Lowered by Royce & Associates LPJuly 27, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Downgraded to Sell Rating by Wall Street ZenJuly 26, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Purchased by Legato Capital Management LLCJuly 24, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by FAS Wealth Partners Inc.July 19, 2025 | marketbeat.comEURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)July 18, 2025 | globenewswire.comWhat Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'July 15, 2025 | sharewise.comSARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?July 15, 2025 | zacks.comWall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?July 15, 2025 | zacks.comWhat Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'July 15, 2025 | zacks.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Buy" by BrokeragesJuly 11, 2025 | marketbeat.comARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle EpinephrineJuly 10, 2025 | seekingalpha.comARS Pharmaceuticals: 'Betting On The Come'July 9, 2025 | seekingalpha.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 4.6% - Should You Buy?July 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePGEN, APGE, SPRY, and ARQT Company DescriptionsApogee Therapeutics NASDAQ:APGE$37.24 -0.51 (-1.35%) Closing price 04:00 PM EasternExtended Trading$37.20 -0.04 (-0.09%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Arcutis Biotherapeutics NASDAQ:ARQT$14.52 +0.23 (+1.61%) Closing price 04:00 PM EasternExtended Trading$14.62 +0.11 (+0.72%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Precigen NASDAQ:PGEN$1.76 +0.09 (+5.39%) Closing price 04:00 PM EasternExtended Trading$1.78 +0.02 (+1.14%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.ARS Pharmaceuticals NASDAQ:SPRY$17.38 +0.20 (+1.16%) Closing price 04:00 PM EasternExtended Trading$17.36 -0.02 (-0.14%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How 2 Deals in 48 Hours Changed Everything for Joby Aviation Here's Why Traders Turned Bullish on Boeing Stock Strategy Insiders Buy In While Analysts Predict Big Upside Yes, You Can Get Dividends in Tech: 3 Stocks With Yield + Upside MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It AMD Outperforming NVIDIA: What’s Behind It and Can It Continue? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
